本帖最后由 老马 于 2013-3-13 13:43 编辑 7 U4 X* E# Y9 y/ o! g9 _
, i! y0 {2 E" w [( o9 r
健择（吉西他滨）+顺铂+阿瓦斯汀% _. u) Y2 F' n4 U/ ~ {
Gemzar +Cisplatin + Avastin
8 l3 v7 c/ h! U# M' uhttp://annonc.oxfordjournals.org/content/21/9/1804.full+ N7 [7 ~6 f1 \8 Z9 W: E$ D; t
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ T, B1 ^7 I5 x+ b: O7 jPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, Z) h: m4 F- Y+ B1 l0 AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& M) [: i$ v5 C' o/ e+ A: U$ i3 f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 629)
8 U2 U4 Z& M0 x# i& S8 P
华为网盘附件：
- h, } e! V T3 o1 r8 M: ~1 [% n【华为网盘】ava.JPG0 P$ S% I3 t: j& K8 k: e
|
显身卡
